Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia

Amyloid-positron emission tomography (PET) imaging of the brain detects elevated amyloid-beta (amyloid-β) neuritic plaques in vivo, which can be helpful in appropriately selected cases of mild cognitive impairment (MCI) and dementia, when Alzheimer’s disease remains a possible etiology, after a comprehensive clinical evaluation. We reviewed cases of cognitively impaired patients who underwent amyloid-PET imaging because of diagnostic uncertainty. Pre- and post-PET elements of diagnosis and management were first compared, to assess impact of scan results on clinical decision-making, and then an analysis of those decisions was undertaken in appropriate clinical situations, to delineate the added value and limitations of amyloid-PET imaging. The potential benefits and limitations of this diagnostic tool are important to understand in an era when the utility of such scans in clinical practice is evolving

P2‐190: Use of an FDG‐PET derived hypometabolic convergence index enrichment strategy to reduce sample sizes in Alzheimer’s disease clinical trials: findings from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/153218/1/alzjjalz2011051076.pd

Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia

Amyloid-positron emission tomography (PET) imaging of the brain detects elevated amyloid-beta (amyloid-β) neuritic plaques in vivo, which can be helpful in appropriately selected cases of mild cognitive impairment (MCI) and dementia, when Alzheimer’s disease remains a possible etiology, after a comprehensive clinical evaluation. We reviewed cases of cognitively impaired patients who underwent amyloid-PET imaging because of diagnostic uncertainty. Pre- and post-PET elements of diagnosis and management were first compared, to assess impact of scan results on clinical decision-making, and then an analysis of those decisions was undertaken in appropriate clinical situations, to delineate the added value and limitations of amyloid-PET imaging. The potential benefits and limitations of this diagnostic tool are important to understand in an era when the utility of such scans in clinical practice is evolving

O4–08–01: Association between the Alzheimer’s disease–related hypometabolic convergence index and clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer’s Disease Neuroimaging Initiative

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/153281/1/alzjjalz201304377.pd

P2‐217: Capitalizing on complementary FDG PET and florbetapir PET data sets to distinguish between early and late mild cognitive impairment using multi‐modal partial least squares

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152928/1/alzjjalz201205924.pd

IC‐P‐155: Association between the Alzheimer’s disease‐related hypometabolic convergence index and clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer’s Disease Neuroimaging Initiative

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152779/1/alzjjalz201305152.pd

Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose.

<label>BACKGROUND</label>We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers.<label>METHODS</label>An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers.<label>RESULTS</label>These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001).<label>CONCLUSIONS</label>The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD

IC‐P‐112: The pattern of cerebral hypometabolism and its association with clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer’s Disease Neuroimaging Initiative

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152819/1/alzjjalz201305109.pd

P3–111: The pattern of cerebral hypometabolism and its association with clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer’s Disease Neuroimaging Initiative

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152964/1/alzjjalz2013051182.pd